Navigation Links
Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
Date:6/22/2011

SAN DIEGO, June 22, 2011 /PRNewswire/ -- Ambrx Inc. today announced that Ho Cho, Ph.D., the company's Chief Technology Officer, will present preclinical data from the company's antibody drug conjugate (ADC) programs at five upcoming scientific conferences. The presentations will include data obtained from recent xenograft studies comparing Ambrx ADCs with those created using other technologies.

"Ambrx technology has been clinically validated as safe and efficacious for creating PEGylated proteins, and we have recently focused our efforts on creating site-specific conjugates of antibodies with best-in-class potential," Dr. Cho said. "Preclinical data obtained from partnered and unpartnered programs show us that the application of our technology to creating ADCs has tremendous potential. We look forward to presenting this promising data to the scientific community over the coming months."

At the IBC Life Sciences' Next Generation Protein Therapeutics Summit in San Francisco, Dr. Cho will deliver a presentation titled "Synthetic Biology Applied to Biotherapeutics" at 1:30 p.m. PDT on June 22, 2011.

At the American Chemical Society's 242nd National Meeting in Denver, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry with an Expanded Genetic Code" at 9 a.m. MDT on August 29, 2011.

At the Cambridge Healthtech Institute's PEGs Europe conference in Hannover, Germany, Dr. Cho will deliver a presentation titled "Protein Medicinal Chemistry Applied to Antibody Drug Conjugates" at 3:05 p.m. CEST on October 11, 2011.

At the World Antibody Drug Conjugate Summit in San Francisco, Dr. Cho will deliver a presentation titled "Optimized Antibody Drug Conjugates with an Expanded Genetic Code" at 10 a.m. PDT on October 27, 2011.

Dr. Cho will also deliver a presentation at the IBC Life Sciences' Empowered Antibody Therapies Conference, held August 1-3, 2011, in San Francisco.

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using its broad biologics platform to create best-in-class therapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx is developing several product candidates in collaboration with Eli Lilly and Company, including a Phase 3 compound expected to be launched commercially in 2013. The company has validated its biologics platform through additional partnerships with Pfizer and Merck & Co Inc.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contacts:

David Schull or Ian Stone
Russo Partners
T: (212) 845-4271
T: (619) 528-2220
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Ambrx Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology
2. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
3. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
4. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
5. Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference
6. Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
7. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
8. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
9. Simulated Environment Concepts to Present at National Eagles and Angels Association New York Meeting
10. Radiation Therapy Services Holdings, Inc. to Present at the Wells Fargo Securities 2011 Healthcare Conference
11. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Direct-to-consumer digital marketing ... and 65% increase in consumable sales, quarter-over-quarter ... DRIO ), a leader in digital health ... Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, ... and minimally invasive smart diabetes management solution. ...
(Date:1/23/2017)... plc, (NYSE: AGN ), a leading global pharmaceutical ... Academy (IHA). Designed to inspire a long-term commitment to Headache ... three-day, intensive overview on research and treatment options. This is ... since the inception of IHA in North America ... in 2014. "Allergan is dedicated ...
(Date:1/23/2017)... 2017  Using Astute Medical,s NephroCheck Test ... acute kidney injury (AKI) after open-heart surgery and ... guidelines significantly improved outcomes by reducing the ... 33 percent, according to a study ... Care Medicine. Experience the interactive ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue ... three-year outcome study on how outdoor behavioral healthcare (OBH) – also known as wilderness ... interpersonal difficulties while experiencing an increased sense of purpose both during and after treatment. ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the January ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s Marches ... people and by all people shines as a bright beacon of determination and ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 23, 2017 , ... Ultimate Medical Academy today announced the ... held March 23-25, 2017 in Tampa, and reminded educators and education leaders to ... include Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
Breaking Medicine News(10 mins):